


Investing for tomorrow, delivering today.

Longterm Care Support Call

09/26/2023

1190 S. St. Francis Drive • Santa Fe, NM 87505 • Phone: 505-827-2613 • Fax: 505-827-2530 • nmhealth.org

Reported COVID-19 New Hospital Admissions Rate per 100,000 Population in the Past Week, by County – United States



COVID-19 hospital admissions levels in U.S. by county


Based on new COVID-19 hospital admissions per 100,000 population

	Total	Percent	% Change
≥ 20.0	27	0.84%	0.16%
10.0 - 19.9	361	11.23%	4.08%
<10.0	2826	87.93%	-4.48%

Time Period: New COVID-19 hospital admissions per 100,000 population (7-day total) are calculated using data from the MMWR week (Sun-Sat) ending September 9, 2023.

https://covid.cdc.gov/covid-data-tracker/#cases_new-admissions-rate-county

COVID-19 New Hospital Admissions and Percentage of Emergency Department (ED) Visits Diagnosed as COVID-19, by Week, in The United States, Reported to CDC




Respiratory Virus Activity

~

Select your state or territory:

New Mexico



https://www.cdc.gov/respiratory-viruses/index.html

Stay Informed About NM COVID Activity




https://cv.nmhealth.org/epidemiology-reports/

Community Transmission for Healthcare Facilities

DOWNLOAD THE COVID-19 COMMUNITY TRANSMISSION REPORT

Levels of Community Transmission – New Mexico Counties September 05, 2023 – September 18, 2023



Community Transmission Report For Healthcare

 <u>https://cv.nmhealth.org/epidemi</u> <u>ology-reports/</u>

Free COVID-19 Tests Are Back

- Starting September 25th you can order 4 free COVID-19 rapid tests per address delivered to your home via US Mail. <u>https://www.covid.gov/tests</u>
- This site also has a tool to see the extended expiration dates on any tests you may already have.
- This could be useful for your staff and residents who live in Assisted or Independent Living

Reporting Requirements



Entities conducting SARS-COV-2/COVID-19 viral testing including all NAAT (PCR) testing, and all testing conducted in a setting operating under a CLIA certificate of waiver, must report positive test results. This includes rapid testing conducted in many settings (e.g., screening testing at schools, correctional facilities, employee testing programs, long-term care facilities, and point-of-care testing performed in pharmacies, medical provider offices, and drive-through testing sites.



The preferred method of reporting SARS-CoV-2/COVID-19 positive test results, including point-of-care or in-house analyzer test results to NMDOH continues to be through an automated or electronic reporting system, like SimpleReport. If a facility does not currently have the capacity to report test results through an automated or electronic reporting system, then the facility should report through the ERD fax line, 505-827-0013.



CMS still requires facilities to report weekly COVID-19 data to NHSN, please see the document titled *"CMS COVID-19 Reporting Requirements for Nursing Homes"* found here: <u>https://www.cdc.gov/nhsn/ltc/covid19/index.html</u>.

Monovalent mRNA Vaccines 2023-2024 Formulation Based on Omicron Sublineage XBB.1.5

Moderna COVID-19 Vaccine (2023-2024) Pfizer-BioNTech COVID-19 Vaccine (2023-2024)

Authorized for people 6 months and older Authorized for people 6 months and older

Everyone 5 years of age and older who are unvaccinated or previously received any number of vaccine doses should receive 1 dose of updated 2023-2024 mRNA COVID vaccine at least 8 weeks after last dose

Ages 12 years and older*

COVID-19 vaccination history prior to updated (2023–2024 Formula) vaccine*	Updated (2023– 2024 Formula) mRNA vaccine	Number of updated (2023–2024 Formula) mRNA doses indicated*	Dosage (mL/ug)	Vaccine vial cap and label colors [§]	Interval between doses
Unvaccinated	Moderna	3	0.5 mL/50 ug	Dark blue cap; blue label	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
	Pfizer-BioNTech	3	0.3 mL/30 ug	Gray cap; gray label	Dose 1 and Dose 2: 3 weeks Dose 2 and Dose 3: At least 4 weeks
1 dose any Moderna	Moderna	2	0.5 mL/50 ug	Dark blue cap; blue label	Dose 1: 4 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Moderna	Moderna	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 4 weeks after last dose
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/30 ug	Gray cap; gray label	Dose 1: 3 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 4 weeks after last dose
3 or more doses any mRNA vaccine	Moderna OR	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose
1 or more doses of Novavax or Janssen, including in combination with any mRNA vaccine dose(s)	Moderna OR	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose

Description of moderate and severe immunocompromising conditions and treatment

Moderate and severe immunocompromising conditions and treatments include but are not limited to:

- Active treatment for solid tumor and hematologic malignancies
- Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
- · Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)
- Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm³, history of an AIDS-defining illness
 without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)

<u>Factors to consider</u> in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.

COVID vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies

Timing of Vaccine Administration

"up-to-date" now means that you have received the most recent age appropriate dose of COVID vaccine

COVID-19, Influenza and RSV vaccines may be simultaneously administered

Vaccines should be administered at different anatomic sites and not combined in the same syringe

People with recent SARS-CoV-2 infection may delay vaccine dose by 3 months from symptom onset or positive test

If you recently received a bivalent booster, the updated 2023-2024 should be given at least 8 weeks later

Contraindications and precautions

CDC considers the conditions listed in Table 3 to be COVID-19 vaccination contraindications and precautions.

Table 3. Contraindications and precautions to COVID-19 vaccination

Medical condition or history	Guidance	Recommended action(s)
History of a severe allergic reaction* (e.g., anaphylaxis†) after a previous dose or to a component of the COVID-19 vaccine ¹	Contraindication	Do not vaccinate with the same COVID-19 vaccine type. ⁵ May administer the alternate COVID-19 vaccine type. ⁵ See <u>Considerations for people with a history of allergies</u> <u>and allergic reactions</u> for additional information.
History of a diagnosed non-severe allergy* to a component of the COVID-19 vaccine*	Precaution	May administer the alternate COVID-19 vaccine type. ⁵ For additional information, see <u>Considerations for</u>
History of a non-severe, immediate (onset less than 4 hours) allergic reaction* after administration of a previous dose of one COVID-19 vaccine type ¹	Precaution	people with a history of allergies and allergic reactions.
Moderate or severe acute illness, with or without fever	Precaution	Defer vaccination until the illness has improved.
History of MIS-C or MIS-A	Precaution	See COVID-19 vaccination and MIS-C and MIS-A.
History of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine	Precaution	A subsequent dose of any COVID-19 vaccine should generally be avoided.
		See <u>COVID-19 vaccination and myocarditis and</u> pericarditis.